Merck CEO Expresses Confidence in Improving Manufacturing Efficiency for Cancer Vaccine with Moderna
Merck CEO Rob Davis told CNBC that the company's cancer vaccine developed in partnership with Moderna is expected to become faster to manufacture over time. The personalized vaccine, which targets individual tumor mutations and pairs with Merck’s Keytruda immunotherapy, currently takes six weeks from sequencing a patient’s tumor to delivery but could be improved as production processes are refined. Davis emphasized that the manufacturing process has been
Topics: Biotech Partnerships Cancer Research Pharmaceuticals